A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children
- Conditions
- Autism Spectrum Disorder
- Interventions
- Drug: Placebo of AST-001
- Registration Number
- NCT06333964
- Lead Sponsor
- Astrogen, Inc.
- Brief Summary
1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD.
2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD.
3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 169
- Those who meet the criteria of diagnostic and statistical manual of mental disorder (DSM)-5 during screening
- During screening period, individuals who are diagnosed with ASD through ADI-R assessment
- Subject with a CGI-S score of 4 or higher as a result of Clinical Global Impression(CGI) evaluation during baseline visit(visit 2)
- Subject or/and legally authorized representative voluntarily agreed to participate in this clinical trial and provided their informed consent by signing the written consent form
- In case of subjects who were receiving non-pharmacological therapy at the time of screening, the non-pharmacological therapy lasted at least 3 months prior to participation in screening and is expected to be sustainable during this clinical trial
- Subject whose legally authorized representative is able to participate in the provision of reliable information about the subject's condition, execute all scheduled site visits, oversee IP administration, fully understand and speak Korean, and conduct survey evaluation regarding the subject
- At the time of screening, subject has the medical history, concomitant condition, or surgical history
- During the screening period, uncontrolled medical conditions,
- During the screening period, display of severe self-harm or injury to others that requires medical treatment, determined by investigator
- At the time of screening, weight over 60kg
- Inappropriate to participate in the trial determined by investigator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description AST-001 AST-001 - Placebo of AST-001 Placebo of AST-001 -
- Primary Outcome Measures
Name Time Method K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II) Baseline, 12week, 24week
- Secondary Outcome Measures
Name Time Method CGI (Clinical Global Impression) Baseline, 4week, 8week, 12week, 18week, 24week SRS-2 (Social Responsiveness Scale-2) Baseline, 4week, 12week, 24week K-PSI-4-SF (Korean-Parenting Stress Index-4th Edition Short Form) Baseline, 12week, 24week
Trial Locations
- Locations (11)
Chungnam National University Hospital
🇰🇷Daejeon, Korea, Republic of
Hanyang University Seoul Hospital
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea, Seoul St. Mary's Hospital
🇰🇷Seoul, Korea, Republic of
Soon Chun Hyang University Hospital Cheonan
🇰🇷Cheonan, Chungcheongnam-do, Korea, Republic of
Jeonbuk National University Hospital
🇰🇷Jeonju, Jeollabuk-do, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Koera University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Hallym University Medical Center
🇰🇷Anyang, Gyeonggi-do, Korea, Republic of
Samsung Changwon Medical Center
🇰🇷Changwon, Gyeongsangnam-do, Korea, Republic of
Pusan National University Yangsan Hospital
🇰🇷Yangsan, Gyeongsangnam-do, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of